



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Mouse *Idh3a* Mutations Cause Retinal Degeneration and Reduced Mitochondrial Function

### Citation for published version:

Findlay, A, Carter, R, Starbuck, B, McKie, L, Novakova, K, Budd, PS, Keighren, M, Marsh, J, Cross, S, Simon, M, Potter, P, Morton, N & Jackson, I 2018, 'Mouse *Idh3a* Mutations Cause Retinal Degeneration and Reduced Mitochondrial Function' *Disease Models & Mechanisms*. DOI: 10.1242/dmm.036426

### Digital Object Identifier (DOI):

[10.1242/dmm.036426](https://doi.org/10.1242/dmm.036426)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Version created as part of publication process; publisher's layout; not normally made publicly available

### Published In:

*Disease Models & Mechanisms*

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Mouse *Idh3a* Mutations Cause Retinal Degeneration and Reduced Mitochondrial Function

Amy S. Findlay<sup>1</sup>, Roderick N. Carter<sup>2</sup>, Becky Starbuck<sup>3</sup>, Lisa McKie<sup>1</sup>, Klára Nováková<sup>1</sup>, Peter S. Budd<sup>1</sup>, Margaret A. Keighren<sup>1</sup>, Joseph A. Marsh<sup>1</sup>, Sally H. Cross<sup>1</sup>, Michelle M. Simon<sup>3</sup>, Paul K. Potter<sup>3</sup>, Nicholas M. Morton<sup>2</sup>, Ian J. Jackson<sup>1,4\*</sup>

1. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU
2. Molecular Metabolism Group, Centre for Cardiovascular Sciences, Queens Medical Research Institute, University of Edinburgh, EH16 4TJ
3. MRC Mammalian Genetics Unit, MRC Harwell Institute, Harwell Campus, Oxfordshire, OX11 0RD
4. Roslin Institute, University of Edinburgh, Edinburgh EH25 9RG

\*corresponding author

### **Summary Statement**

We show that partial loss of function mutations in the *ldh3a* gene lead to retinal degeneration due to compromised mitochondrial function. Complete loss of *ldh3a*, however, is embryonically lethal.

## Abstract

Isocitrate dehydrogenase (IDH) is an enzyme required for the production of  $\alpha$ -ketoglutarate from isocitrate. IDH3 generates the NADH used in the mitochondria for ATP production, and is a tetramer made up of two  $\alpha$ , a  $\beta$  and a  $\gamma$  subunit. Loss of function and missense mutations in both *IDH3A* and *IDH3B* have previously been implicated in families exhibiting retinal degeneration. Using mouse models we have investigated the role of IDH3 in retinal disease and mitochondrial function.

We identified mice with late-onset retinal degeneration in a screen of ageing mice carrying an ENU-induced mutation, E229K, in *Idh3a*. Mice homozygous for this mutation exhibit signs of retinal stress, indicated by GFAP staining, as early as 3 months, but no other tissues appear to be affected. We produced a knockout of *Idh3a* and found that homozygous mice do not survive past early embryogenesis. *Idh3a*<sup>-/E229K</sup> compound heterozygous mutants exhibit a more severe retinal degeneration when compared to *Idh3a*<sup>E229K/E229K</sup>. Analysis of mitochondrial function in mutant cell lines highlighted a reduction in mitochondrial maximal respiration and reserve capacity levels in both *Idh3a*<sup>E229K/E229K</sup> and *Idh3a*<sup>-/E229K</sup> cells. Loss-of function *Idh3b* mutants do not exhibit the same retinal degeneration phenotype, with no signs of retinal stress or reduction in mitochondrial respiration.

It has been previously reported that the retina operates with a limited mitochondrial reserve capacity and we suggest that this, in combination with the reduced reserve capacity in mutants, explains the degenerative phenotype observed in *Idh3a* mutant mice.

## Introduction

Mitochondrial diseases are highly diverse: over 220 different genes have been identified which can cause diseases of the mitochondria and these diseases have a wide range of pathologies (Koopman et al., 2012). Common to many of the diseases, however, are neurological or neuromuscular manifestations, including retinal disease. We have identified a missense mutation in the gene encoding a subunit of the tricarboxylic acid (TCA) cycle enzyme isocitrate dehydrogenase 3 (IDH3) as causing a retinal degeneration phenotype in mice. There are three isocitrate dehydrogenase isozymes in mammals. IDH1 and IDH2 are both homodimers that catalyse the decarboxylation of isocitrate to  $\alpha$ -ketoglutarate with the concomitant reduction of NADP to NADPH. IDH1 is cytoplasmic whilst IDH2 is localised to the mitochondria. No inherited disease has been associated with *IDH1* mutations, but mutations in *IDH2* cause a metabolic disease, D-2-Hydroxyglutaric Aciduria, with a range of features including epilepsy, hypotonia and other neurological manifestations (Kranendijk et al., 2010). *IDH1* or 2 are found to be mutated in a high proportion of glioblastomas and other tumours of the nervous system. By contrast, IDH3 is a heterotetramer, composed of two alpha, a beta, and a gamma subunits, encoded by three genes. IDH3 is located in the mitochondria where the conversion of isocitrate to  $\alpha$ -ketoglutarate is necessary for the TCA cycle to progress and generates NADH, which feeds into oxidative phosphorylation to generate ATP. No recurrent mutations in any of the *IDH3* genes have been described in tumours.

A number of patients have been described with a variety of mutations in *IDH3A* (Fattal-Valevski et al., 2017; Pierrache et al., 2017). The most severe of these, a homozygous missense mutation (p.Pro304His), exhibited neurological defects from birth, possibly due to a failure during development, as well as retinal degeneration. The patient however showed no symptoms of muscle weakness typically associated with mitochondrial deficiencies. The remaining patients, with biallelic variants, all exhibited childhood onset of retinal degeneration, and some had pseudocoloboma of the macula. Pseudocoloboma is not a developmental defect but is due to degeneration of the retina. Seven different alleles were found in four different

families all predicted to be pathogenic – including two which could potentially cause nonsense mediated decay. The other five, all missense mutations, are anticipated to be damaging. Two families with homozygous mutations in *IDH3B*, and which exhibited non-syndromic retinal degeneration, have also been described previously (Hartong et al., 2008). None of these patients showed symptoms of mitochondrial dysfunction other than retinitis pigmentosa.

We have identified a missense mutation, E229K, in mouse *Idh3a* which is associated with late-onset retinal degeneration. In addition we generated a complete loss-of-function mutation in this gene and show that it is early embryonic lethal. This mutation, when combined with the missense mutation *Idh3a*<sup>E229K</sup> results in a more rapid retinal degeneration than the missense homozygotes. Photoreceptors of the retina have a particularly high energy requirement, and the mitochondria of these cells function at 70-80% of their maximal rate, leaving limited reserve capacity (Kooragayala et al., 2015). This most likely accounts for the sensitivity of the retina to mitochondrial mutations. On the other hand, a loss of function mutation in *Idh3b* is viable and has no detectable abnormal phenotype. The retina of these mice are normal up to 6 months of age. We have analysed the mitochondrial function in cells with *Idh3* mutations and find the maximum and reserve capacity of *Idh3a* mutant cells to be reduced. However, cells lacking IDH3B show no detectable mitochondrial defect.

## Results

Following a screen for ENU-induced recessive mutations with an age-dependent phenotype, we identified a mouse line which exhibited loss of vision and retinal degeneration associated with increasing age (Potter et al., 2016). When subjected to a moving visual stimulus within an optokinetic drum (OKD) at 12 months of age, a subset of the littermates in this cross responded with the stereotypical head movement only at ~0.2 cycles per degree (c/d), compared to >0.3 c/d for phenotypically wildtype littermates. These mice maintained a diminished response at

18 months (**Fig. 1A**). The same mice had abnormal retina, identified by indirect ophthalmoscopy and documented by fundal imaging at 7 months (**Fig. 1B**). The dark patches on the retinal images are indicative of retinal degeneration. No other overt phenotypes were detected in the mice up to 18 months of age (Table S1).

Genotyping of the affected littermates in this cross revealed a single common region of homozygosity on chromosome 9, between 50.1 and 74.8 Mb. Analysis of whole genome sequence of the founder male for this line found two candidate protein coding mutations in the interval, heterozygous in the founder; sorting nexin 33 (*Snx33*) and the alpha subunit of Isocitrate Dehydrogenase 3 (*Idh3a*). The *Snx33* mutation was not present in the mutant line, presumably as it is on the unaffected chromosome. We considered the missense mutation, E229K in *Idh3a*, to be the likely causative mutation, as human patients with mutations in either *IDH3A* or *B* exhibit retinal degeneration (Fattal-Valevski et al., 2017; Hartong et al., 2008; Pierrache et al., 2017). To confirm *Idh3a* as the causative gene we used CRISPR/Cas9 to introduce a loss-of-function mutation. We generated an insertion of 5bp into exon 7 of the gene, c.702\_703InsGTACT, termed *Idh3a<sup>em1Jkn</sup>*, abbreviated herein as *Idh3a<sup>-</sup>*.

We bred compound heterozygous mice for *Idh3a<sup>-</sup>* and *Idh3a<sup>E229K</sup>* and examined their eyes and visual function. As documented below these mice have rapid retinal degeneration, demonstrating lack of complementation between the two alleles, and indicating that the E229K mutation is the cause of retinal degeneration in the mice found in the screen.

### Structural analysis of missense mutations

Residue Glu229 is located at the rim (Levy, 2010) of the heterodimeric interface formed between IDH3A and IDH3G (**Fig. 1C**), contributing only a small amount of surface area (9.7 Å<sup>2</sup>) to the much larger interface (4401 Å<sup>2</sup>). However, molecular modelling of the E229K mutation, which replaces a negatively charged side chain with a positive charge, shows that it is likely to moderately disrupt the IDH3A:IDH3G interaction with little effect on the stability of the IDH3A monomer (**Fig. 1D**). In contrast, all five of the previous identified damaging IDH3A mutations are located

away from the interface, either in the protein interior (A175V, M239T, P304H, M313T) or on the protein surface (R316C). All of these mutations are predicted to destabilize the IDH3A monomer, but not the interaction with IDH3G.

### Loss of IDH3A is lethal

As IDH3 is a critical part of the mitochondrial tricarboxylic acid (TCA) cycle, we asked whether the loss-of-function insertion allele was compatible with life. We intercrossed mice carrying the *Idh3a*<sup>-</sup> allele. No homozygous mice were recovered at weaning from a total of 120 genotyped, indicating that a complete loss of function of *Idh3a* is lethal. We examined embryos from intercrosses at different stages. No homozygous embryos were recovered at embryonic day (E) 10.5 or E12.5. At E8.5 only remains of developmentally delayed embryos were recovered, indicating lethality to be early in development (**Table 1**). We confirmed loss of function of *Idh3a* by Western blot analysis of *Idh3a*<sup>-/+</sup> and *Idh3a*<sup>-/E229K</sup> mutant embryonic fibroblasts which showed a reduction in Idh3a protein when compared to *Idh3a*<sup>+/+</sup>, *Idh3a*<sup>E229K/+</sup>, *Idh3a*<sup>E229K/E229K</sup> cell lines (**Fig. S1**). Heterozygous littermates were aged to one year but no retinal degeneration was observed indicating that one functional allele of the gene is sufficient (**Fig. S2**).

### Onset of retinal degeneration is early and rapid

We analysed the onset and progression of the retinal degeneration of both *Idh3a*<sup>E229K/E229K</sup> and *Idh3a*<sup>-/E229K</sup> mice by immunostaining for glial fibrillary acidic protein (GFAP), expression of which is a sign of reactive gliosis of the Müller cells and an early indicator of stress within the retina (Eisenfeld et al., 1984). We also stained histological sections to assess retinal structure and integrity. From post natal day 30 (P30), *Idh3a*<sup>-/E229K</sup> mice exhibit GFAP staining throughout the retina (**Fig. 2A**), highlighting intermediate fibrils protruding from the ganglion cell layer to the outer nuclei layer (ONL). Nevertheless, at this stage *Idh3a*<sup>-/E229K</sup> mice still retain the same number of nuclei in the ONL, the nuclei of the photoreceptors, as control littermates (**Fig. 2C**) throughout almost the entire retina with only a slight decrease in the nasal periphery. However, by P60 the ONL has lost a significant portion of nuclei indicating



a loss in photoreceptor cells (**Fig. 2B**). This loss progresses further by P90 (**Fig. 2B**). No other cells within the retina appear to be lost during this degeneration.

By contrast, *Idh3a*<sup>E229K/E229K</sup> mice up to P60 show no signs of reactive gliosis or loss of cells (**Fig. 2A**). It is not until P90 that they begin to show GFAP staining (**Fig. 2A**), and the mice begin to lose photoreceptor nuclei (**Fig. 2D**). Again no other cells appear to be lost during this time.

### **Prior to the loss of photoreceptors mice exhibit normal retinal function.**

We carried out electroretinography (ERG) analysis of *Idh3a*<sup>-E229K</sup> mice at P30. Although some reactive gliosis is detected at this stage, they nevertheless showed a normal response to light stimulus. A-wave amplitudes are not significantly different to wild type and heterozygous (*Idh3a*<sup>-/+</sup> and *Idh3a*<sup>E229K/+</sup>) littermates shown by One-way ANOVA ( $F(3,10) = 0.7970$ ,  $p = 0.5232$ ) and the trace produced shows no abnormalities (**Figs. 3A & C**). The same mice tested at P60 showed a significantly reduced a-wave response by One-way ANOVA with Tukey post hoc tests ( $F(3,9) = 32.66$ ,  $p < 0.0001$ ) and mice exhibited a flatline ERG trace (**Figs. 3B & C**). The loss of a scotopic response is concurrent with the loss of photoreceptors observed in **Fig. 2B**.

The scotopic ERG responses of *Idh3a*<sup>E229K/E229K</sup> mice were tested at P60. Homozygous mutants showed no significant difference ( $p = 0.9604$ ) when compared to wild type littermates, showing a normal a-wave amplitude and trace (**Figs. 3D & F**). However, by 4 months of age the a-wave amplitudes of scotopic ERG responses have significantly reduced in *Idh3a*<sup>E229K/E229K</sup> compared to wild type litter mates ( $p = 0.0491$  Unpaired T test with Welch's correction) (**Figs. 3E & F**).

### **Mitochondria show a reduced maximal and reserve capacity**

As IDH3 is an essential part of the mitochondrial TCA cycle, we investigated how the *Idh3a* mutations affected the overall function of mitochondria (**Fig. 4A**). It has been previously shown (Kooragayala et al., 2015) that photoreceptors have a high oxygen demand and in consequence their mitochondria are at maximum capacity. In order to measure the mitochondrial function in cells that are not already at maximum capacity we derived multiple, independent fibroblast lines from *Idh3a*<sup>E229K/E229K</sup> and *Idh3a*<sup>-E229K</sup> embryos, and heterozygous and wild-type littermates. When tested, the homozygous

and compound heterozygous mutant cell lines showed a trend to lower basal (**Fig. 4D**), ATP (**Fig. 4E**) and leaked respiration (**Fig. 4F**), although not statistically significant. However, both *Idh3a*<sup>E229K/E229K</sup> and *Idh3a*<sup>-/E229K</sup> cell lines did exhibit a significant decrease in maximal respiration (**Fig. 4B**) and spare respiratory capacity (**Fig. 4C**). Spare respiratory capacity (SRC) is a direct measure of a cell's ability to deal with respiratory stress. Mitochondrial dysfunction can result in cell death due to oxidative stress. We asked if the mitochondrial defect in this case led to an excess of reactive oxygen species in the cells; we found no difference between mutant and wild type cells (**Fig. S3A**). Similarly we measured the amount of mitochondrial proteins (**Fig. S3B**) and all cell lines showed similar amounts indicating no change in mitochondrial number.

#### ***Idh3b* mutants do not exhibit the same phenotype as *Idh3a* mutants**

As human patients with apparent loss-of-function mutations in *IDH3B* seem only to have retinal degeneration, we produced a CRISPR Cas9-induced mutation in the mouse *Idh3b* gene. We identified an 8bp deletion allele, c.478\_487delCCAATGGA, and intercrossed carriers of this mutation, here abbreviated to *Idh3b*<sup>-</sup>. Homozygous animals were identified at normal Mendelian ratio.

Protein extracts from homozygous livers were probed on immunoblot following electrophoresis and no protein could be detected, indicating the mutation is a loss of function (**Fig. 5F**).

*Idh3b*<sup>-/-</sup> mice were aged and analysed in the same manner as *Idh3a* mutant mice. By P180 we observed no signs of retinal degeneration. There is no observed upregulation of GFAP when compared to wild type littermate controls (**Fig. 5A**). ERG analysis showed that homozygous mutants exhibited normal scotopic responses (**Fig. 5B**). Extracellular flux analysis of fibroblasts produced from mutant embryos also showed that these mutant cell lines' mitochondria were not affected by the loss of *Idh3b* with normal reserve capacity and maximum respiration levels (**Figs. 5C-E**).

## Discussion

In this study we investigate the retinal degeneration in a mouse line identified in a recessive ENU screen. This is the first mouse model of IDH3A-related chronic retinal degeneration described, and closely mirrors the phenotype observed in patients. However, it is not possible to model the pseudocoloboma of the macula seen in human patients in mice, as they lack a macula. Through the course of the investigation we confirmed the genetic source of the phenotype to be a missense mutation in the *Idh3a* gene. The amino acid mutated in the *Idh3a*<sup>E229K</sup> mouse is within the highly conserved nucleotide binding domain observed in both NAD- and NADP- dependent dehydrogenases of animals, including *C. elegans* and *Drosophila* (Pierrache et al., 2017). E229 is close to the amino acid critical for binding the divalent cation necessary for activity (D233), and is within a short segment of beta-sheet (Ma et al., 2017b).

Mutation of such a highly conserved amino acid residue, in an important part of the enzyme might suggest that it would cause complete loss of function, but the fact that the insertion (null) mutation is embryonic lethal indicates that the E229K allele is actually a partial loss of function mutation. The human mutations that have been identified in patients with retinitis pigmentosa (RP) presumably also include partial loss of function alleles. Two mutations are clear nulls; a frameshift and a stop-gained. Each of these is in a compound heterozygote with a likely partial loss of function mutation: M239C and R316H. One patient is homozygous for A175V, again presumed to be a partial loss of function. A further patient was compound heterozygous for M313T and P304H. The latter mutation was also identified as homozygous in a child with severe neurological defects in addition to retinal degeneration, and thus M313T is another likely partial loss of function allele. The three patients with one clear null allele included both who had macular pseudocoloboma in addition to RP, suggesting that it is a further reduction in IDH3A activity that results in the additional pathology. Notwithstanding the variation in severity of the mutations, all the mutated amino acids are completely conserved across animals from mammals to *Drosophila* and *C.elegans*. Structural modelling suggests that all 5 human mutations destabilize the

protein and thus we suggest cause severe loss, but not complete absence, of this catalytic subunit.

Mice compound heterozygous for the missense and insertion mutations exhibited a severe form of retinal degeneration, but have no other detectable abnormal phenotypes. A single copy of the *Idh3a*<sup>E229K</sup> allele provides sufficient IDH3 function for apparently normal development and physiology, except in the photoreceptors.

As previously reported (Kooragayala et al., 2015), photoreceptor cells operate at about 70-80% of their mitochondria's maximal capacity which means they have little to no reserve capacity to use when under metabolic respiratory stress. *Idh3a*<sup>E229K/E229K</sup> and *Idh3a*<sup>-/E229K</sup> embryonic fibroblasts have a much lower maximal and reserve capacity compared to control cells. This lowered reserve capacity of mutant mitochondria combined with the already decreased reserve capacity of photoreceptor cells may explain the non-syndromic retinal degeneration phenotype observed. Much like the human patients previously reported, mice with the more severe allele combined with the missense allele exhibit a more severe form of degeneration, although extracellular flux analysis shows that cells have a similar decrease in reserve and maximal respiration.

By using MEF cells the mitochondrial function of mutant mice was observed in an unstressed system. Although the mice showed no overt phenotype other than retinal degeneration, their mitochondria in MEFs exhibited a significant reduction of spare respiratory capacity. Reduction of spare respiratory capacity has previously been shown to induce cell death in both neurons and cardio myocytes (Pfleger et al., 2015; Yadava and Nicholls, 2007). This reduction is thought to induce cell death either by increasing the amount of reactive oxygen species until a threshold is met and the cells succumb or causing a reduction in the amount of ATP produced by the electron transport chain, caused by a decrease in the availability of substrates (Sansbury et al., 2011; Yadava and Nicholls, 2007). Both of these could explain the degenerative phenotype observed in the *Idh3a* mutant mice, within which the catalytic sub unit of the Idh3 enzyme has reduced or partial function.

The presence of more than one IDH enzyme within the mitochondria has been used as evidence for redundant function and the viability of human patients apparently lacking IDH3B function led others to suggest that it is IDH2 that is the main Krebs Cycle enzyme in all tissues except the retina (Hartong et al., 2008). As we have shown that loss of *Idh3a* is lethal early in development, it is clear that IDH2 cannot compensate, and it is the difference between loss of the catalytic subunit and the regulatory subunit that that results in the different outcomes. Furthermore, we used RT-PCR to confirm the expression *Idh2* in the mouse retina, as well as all three subunits of *Idh3*, (**Fig. S1**) indicating that it is not lack of IDH2 in the retina that results in retinal degeneration. On the other hand, when *Idh3a* activity was knocked down in INS-1 832/13 beta cells, glucose dependent production of  $\alpha$ -ketoglutarate was greater than when both *Idh3a* and *Idh2* were knocked down (MacDonald et al., 2013). This indicates that IDH2 can at least partially make up for the loss of IDH3 in this assay. A compensatory mechanism for loss of IDH3 potentially would be the conversion of NADPH, produced by IDH2, to NADH by the enzyme nicotinamide nucleotide transhydrogenase (NNT)(Hoek and Rydström, 1988). This NADH would then be able to participate on oxidative phosphorylation as normal. Furthermore, the gene encoding NNT is mutated in the C57BL6/J strain(Mekada et al., 2009). However, we bred the mice in this study with C57BL6/N, with a normal *Nnt* gene before backcrossing and selecting study animals that did not have the mutant *Nnt* gene. The lethality of the *Idh3a* knock out allele indicates that NNT is unable to enable compensation *in vivo*.

In contrast to *Idh3a* mutants, *Idh3b* mutant mice are fully viable, and show no signs of retinal degeneration within six months of age. Histology and ERG analysis show no significant loss of retinal structure or function. This is also shown in the results of extracellular flux analysis whereby *Idh3b* mutant embryonic fibroblasts cells do not show compromised mitochondrial activity. The human patients with clear null mutations in *IDH3B* develop RP in adulthood; the mutant mice may not live long enough to develop retinal degeneration, or this may simply reflect species differences. Species differences in response to enzymatic dysfunction could also, of course, impact the phenotype of the *Idh3a* mutations. The  $\alpha$  subunit of IDH3, encoded by *Idh3a*, is responsible for the catalytic activity (Bzymek and Colman, 2007). The alpha subunit

alone is inactive and requires the beta and gamma subunits, encoded by *Idh3b* and *Idh3g*. Dimers of  $\alpha\gamma$  or  $\alpha\beta$  have activity, but vary greatly in their properties. *In vitro*,  $\alpha\gamma$  dimers have 36% the specific activity of the heterotetramer, whilst  $\alpha\beta$  dimers have only 16%. Furthermore,  $\alpha\gamma$  dimers are activated at low concentrations of ATP, whilst  $\alpha\beta$  dimers are inhibited. The substrate, isocitrate, activates both the heterotetramer and the  $\alpha\gamma$  dimers, but has no effect on the  $\alpha\beta$  dimers (Ma et al., 2017b). We believe the catalytic activity of the  $\alpha\gamma$  heterodimers explains the lack, or perhaps delay, of a degenerative phenotype in *Idh3b* mutant mice. This also explains why loss of function *IDH3B* patients exhibit milder symptoms and at a much later age than patients with *IDH3A* mutations. In addition, the E229K mutation we describe here is likely to be interfering with the  $\alpha/\gamma$  interaction, indicating that this is important for full activity.

Mutation of many different mitochondrial protein-coding genes can each lead to inherited diseases, with a range of phenotypes. Although there are some common phenotypic consequences, principal being neurological manifestations, there is no clear pattern that can predict the outcome of a particular gene mutation (Munnich, 2008; Rustin et al., 1997). Even amongst genes of the TCA cycle, there is a range of consequences. Some mutations in the mitochondrial aconitase gene (*ACO2*), similar to *IDH3A*, can result in severe neurological disease, progressive optic atrophy and retinal degeneration (Metodiev et al., 2014), whilst other mutations in the same gene can give optic atrophy only. Progressive neurodegenerative disease also arises from mutations in the gene for the TCA cycle enzyme  $\alpha$ -ketoglutarate dehydrogenase. Succinate dehydrogenase (*SDHA*) mutations not only can result in the severe neurological disorder Leigh Syndrome, but also in one extended family can cause dilated cardiomyopathy. Mutations in the gene for another succinate dehydrogenase subunit (*SDHD*) are also a cause of encephalomyopathy. Muscle involvement in addition to neurological disease is also seen in mutations of the malate dehydrogenase gene, *MDH2*.

The high energy demand of the nervous system, and in particular the retina, makes these cells particularly sensitive to deficiencies in mitochondrial function. In our novel mouse models we show that total loss of the TCA cycle enzyme IDH3 is early

embryonic lethal, indicating that the mitochondrial enzyme IDH2 cannot compensate. However, partial loss of function, modelling human patients, results only in retinal degeneration. Modelling human patient mutations in which *Idh3b*, the regulatory subunit of IDH3, is absent does not result in retinal degeneration in mice within 6 months of age, reflecting the later onset of RP in the patients. The mechanism of cell death in this and other mitochondrial retinopathies is not fully understood and it remains to be addressed whether therapeutic options exist.

## Materials and Methods

### Mice

*Idh3a<sup>mpc201H</sup>*, here denoted *Idh3a<sup>E229K</sup>*, mice were produced in a recessive ENU screen at MRC Harwell (Potter et al., 2016). *Idh3a<sup>em1Jkn</sup>* mice were made by microinjection of nuclear CRISPR Cas9 nickase vectors px335 together containing two guide RNAs targeting exon 7 (Table 2) to minimise off target effects. Sequencing identified a 5bp insertion mutation, c.702\_703InsGTACT, in the gene.

*Idh3b<sup>em1Jkn</sup>* mice were made by microinjection of CRISPR gRNA targeting exon 5 and Cas9 protein into the pronucleus of fertilised eggs (**Table 2**). Sequencing identified an 8bp deletion mutation, c.478\_487delCCAATGGA, in the gene. gRNA were chosen with low off target predictions and mice were back crossed onto C57BL6/J prior to breeding. All animal work was approved by a University of Edinburgh internal ethics committee and was performed in accordance with the institutional guidelines under license by the UK Home Office.

### Immunohistochemistry

Mice were culled and eyes were enucleated and placed into Davidson's fixative for 1 hour (cryosectioning) or overnight (wax embedding). For cryosectioning eyes were removed from Davidson's fixative and placed into 10%, 15% and 20% sucrose in PBS for 15 mins, 15 mins and overnight respectively. Eyes were then embedded using OCT cryopreservant and kept at -80°C until sectioned. For wax preservation eyes were removed from Davidson's fix and placed successively into 70%, 80%, 90% and 100% ethanol, xylene twice and then paraffin each for 45 mins.

Heamatoxylin and Eosin staining was performed on 8  $\mu\text{m}$  paraffin tissue sections and imaged on Zeiss Axioplan 2 Brightfield microscope. Glial Fibrillary Acidic Protein (GFAP) antibody (ab7260, Abcam) and Alexa Fluor 488 donkey anti-rabbit antibody (A21206, Invitrogen) were used on 8  $\mu\text{m}$  frozen sections 1:100 and 1:300 respectively. Slides were imaged on a Nikon A1R microscope.

### **Generation of Mouse Embryonic Fibroblast cells**

Mouse embryonic fibroblast (MEF) cells were generated using E12.5 – 14.5 embryos as described in (Takahashi and Yamanaka, 2006) using Gibco Opti-MEM media (Thermo Fisher) with 10% Fetal Calf Serum and grown in hypoxic conditions (5%  $\text{CO}_2$ , 3%  $\text{O}_2$ ). Cells were passaged three times before use, and littermate controls were used where possible.

### **Electroretinogram**

All mice undergoing an ERG were dark adapted for at least 2 hours prior to the procedure, and experiments were carried out in a darkened room under red light using an HMsERG system (Ocuscience). Mice were anesthetized using isoflurane and pupils were dilated through the topical application of 1% w/v tropicamide before being placed on a heated ERG plate. Three grounding electrodes were used subcutaneously (tail, and each cheek) and silver embedded electrodes were placed on the cornea held in place with a contact lens. A standard ISCEV protocol was used which recorded scotopic responses before a 10 min light adaption phase in order to record photopic responses. 3  $\text{cd.s/m}^2$  light intensity scotopic responses were used for analysis.

### **Extracellular Flux Analysis**

Mitochondrial activity of Mouse Embryonic Fibroblast (MEF) cells was analysed using the Seahorse Extracellular Flux Analyser, XF<sup>e</sup>24 (Agilent) as described in (Lee et al., 2016). Cells were seeded into a 24 well plate, 15,000 per well, the day before so cells were 90% confluent at the time of the assay (mutant cell lines appear to proliferate at same rate as control cells). Oxygen consumption (OCR) was measured from cells in XF Assay media supplemented with 10mM Glucose and 2mM pyruvate (pH adjusted to 7.4 at 37°C). After 3 basal OCR measurements were obtained, OCR was measured following sequential injection of mitochondrial drugs (3 measurements per drug injection); Oligomycin (Port A, 1  $\mu\text{M}$ ), FCCP (Port B – 3.5  $\mu\text{M}$ ), Antimycin and Rotenone



(Port C, 1  $\mu$ M). Each measurement was derived from the rate of change in oxygen following a standard protocol (Mix: 3minutes, Wait: 2 minutes, Measure: 3 minutes). Results were then standardized to cell number by Sulforhodamine B assay, and results were reported by 540 absorption.

### **Optokinetic Reflex Measurement**

We assessed the visual acuity of the mice in the ENU screen using a virtual reality optokinetic system as described by (Douglas et al., 2005) and manufactured by Cerebral Mechanics Inc (cerebralmechanics.com). In brief we observe the head tracking response of the mouse to a variable density moving grating. The mouse is positioned within a cabinet formed of monitors on which a virtual drum made of a vertical grating is generated by computer. The grating density is varied to determine the point at which the head tracking stops, showing the grating is no longer perceived.

### **Structural Analysis**

The effects of the missense mutations on the crystal structure of the IDH3 $\alpha$ :IDH3 $\beta$  heterodimer (PDB ID: 5GRI) (Ma et al., 2017a) were modelled using the program FoldX(Guerois et al., 2002). The predicted effect on monomer stability ( $\Delta\Delta G$ ) was calculated with the FoldX BuildModel function, using the IDH3A subunit in isolation from the complex. The predicted change in interaction strength was calculated as the difference between the change in stability for the heterodimeric complex and the monomer.

### **Western Blot**

Protein samples were ran on a 4-12% Tris-Bis gel (Invitrogen) and transferred onto a PVDF membrane. Alpha-tubulin (T5168, Sigma), Total OXPHOS (ab110413, Abcam), Idh3a (15909-1-AP, Proteintech) and Idh3b (ab121016, Abcam) were all diluted 1:1000 in PBS with 5% marvel and incubated overnight at 4°C. Horse radish peroxidase conjugate; anti-mouse (NA931V, GE Healthcare Life Sciences), anti-rabbit (NA934V, GE Healthcare Life Sciences) and anti-goat (SC-2020, Santa Cruz) were diluted 1:7000 in PBS with 5% marvel and incubated at room temperature for 1 hour.

### **Reactive Oxygen Species Detection**

An Image-iT™ LIVE Green Reactive Oxygen Species Detection Kit (I36007, Invitrogen) was used as per manufacturer's instructions. Cells were imaged using a Nikon A1R microscope and analysis of fluorescent levels was done using ImageJ and normalized to DAPI fluorescent levels.

### **Competing Interests**

The authors have no financial or competing interests declared.

### **Funding**

This research was funded by core support to MRC Human Genetics Unit and to MRC Harwell Institute.

RNC and NMM were supported by a Wellcome Trust Investigator Award (100981/Z/13/Z) to NMM.

### **Author Contributions Statement**


## References

- Bzymek, K. P. & Colman, R. F.** (2007). Role of  $\alpha$ -Asp181,  $\beta$ -Asp192, and  $\gamma$ -Asp190 in the distinctive subunits of human NAD-specific isocitrate dehydrogenase. *Biochemistry*, **46**(18), pp 5391-5397.
- Douglas, R., Alam, N., Silver, B., McGill, T., Tschetter, W. & Prusky, G.** (2005). Independent visual threshold measurements in the two eyes of freely moving rats and mice using a virtual-reality optokinetic system. *Visual neuroscience*, **22**(5), pp 677-684.
- Eisenfeld, A. J., Bunt-Milam, A. & Sarthy, P. V.** (1984). Müller cell expression of glial fibrillary acidic protein after genetic and experimental photoreceptor degeneration in the rat retina. *Investigative ophthalmology & visual science*, **25**(11), pp 1321-1328.
- Fattal-Valevski, A., Eliyahu, H., Fraenkel, N. D., Elmaliach, G., Hausman-Kedem, M., Shaag, A., Mandel, D., Pines, O. & Elpeleg, O.** (2017). Homozygous mutation, p. Pro304His, in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy. *neurogenetics*, **18**(1), pp 57-61.
- Guerois, R., Nielsen, J. E. & Serrano, L.** (2002). Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. *Journal of molecular biology*, **320**(2), pp 369-387.
- Hartong, D. T., Dange, M., McGee, T. L., Berson, E. L., Dryja, T. P. & Colman, R. F.** (2008). Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle. *Nature genetics*, **40**(10), pp 1230.
- Hoek, J. B. & Rydström, J.** (1988). Physiological roles of nicotinamide nucleotide transhydrogenase. *Biochemical Journal*, **254**(1), pp 1.
- Koopman, W. J., Willems, P. H. & Smeitink, J. A.** (2012). Monogenic mitochondrial disorders. *New England Journal of Medicine*, **366**(12), pp 1132-1141.
- Kooragayala, K., Gotoh, N., Cogliati, T., Nellisery, J., Kaden, T. R., French, S., Balaban, R., Li, W., Covian, R. & Swaroop, A.** (2015). Quantification of oxygen consumption in retina ex vivo demonstrates limited reserve capacity of photoreceptor mitochondria. *Investigative ophthalmology & visual science*, **56**(13), pp 8428-8436.
- Kranendijk, M., Struys, E. A., Van Schaftingen, E., Gibson, K. M., Kanhai, W. A., Van der Knaap, M. S., Amiel, J., Buist, N. R., Das, A. M. & de Klerk, J. B.** (2010). IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. *Science*, **330**(6002), pp 336-336.

- Lee, W.-H., Higuchi, H., Ikeda, S., Macke, E. L., Takimoto, T., Pattnaik, B. R., Liu, C., Chu, L.-F., Siepka, S. M. & Krentz, K. J. (2016). Mouse Tmem135 mutation reveals a mechanism involving mitochondrial dynamics that leads to age-dependent retinal pathologies. *elife*, **5**(
- Levy, E. D. (2010). A simple definition of structural regions in proteins and its use in analyzing interface evolution. *Journal of molecular biology*, **403**(4), pp 660-670.
- Ma, T., Peng, Y., Huang, W. & Ding, J. (2017a). Molecular mechanism of the allosteric regulation of the  $\alpha\gamma$  heterodimer of human NAD-dependent isocitrate dehydrogenase. *Scientific reports*, **7**(40921).
- Ma, T., Peng, Y., Huang, W., Liu, Y. & Ding, J. (2017b). The  $\beta$  and  $\gamma$  subunits play distinct functional roles in the  $\alpha_2\beta\gamma$  heterotetramer of human NAD-dependent isocitrate dehydrogenase. *Scientific reports*, **7**(41882).
- MacDonald, M. J., Brown, L. J., Longacre, M. J., Stoker, S. W. & Kendrick, M. A. (2013). Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion. *Biochimica et Biophysica Acta (BBA)-General Subjects*, **1830**(11), pp 5104-5111.
- Mekada, K., Abe, K., Murakami, A., Nakamura, S., Nakata, H., Moriwaki, K., Obata, Y. & Yoshiki, A. (2009). Genetic differences among C57BL/6 substrains. *Experimental Animals*, **58**(2), pp 141-149.
- Metodiev, M. D., Gerber, S., Hubert, L., Delahodde, A., Chretien, D., Gérard, X., Amati-Bonneau, P., Giacomotto, M.-C., Boddaert, N. & Kaminska, A. (2014). Mutations in the tricarboxylic acid cycle enzyme, aconitase 2, cause either isolated or syndromic optic neuropathy with encephalopathy and cerebellar atrophy. *Journal of medical genetics*, jmedgenet-2014-102532.
- Munnich, A. (2008). Casting an eye on the Krebs cycle. *Nature genetics*, **40**(10), pp 1148.
- Pfleger, J., He, M. & Abdellatif, M. (2015). Mitochondrial complex II is a source of the reserve respiratory capacity that is regulated by metabolic sensors and promotes cell survival. *Cell death & disease*, **6**(7), pp e1835.
- Pierrache, L. H., Kimchi, A., Ratnapriya, R., Roberts, L., Astuti, G. D., Obolensky, A., Beryozkin, A., Tjon-Fo-Sang, M. J., Schuil, J. & Klaver, C. C. (2017). Whole-exome sequencing identifies biallelic IDH3A variants as a cause of retinitis pigmentosa accompanied by pseudocoloboma. *Ophthalmology*, **124**(7), pp 992-1003.

- Potter, P. K., Bowl, M. R., Jeyarajan, P., Wisby, L., Blease, A., Goldsworthy, M. E., Simon, M. M., Greenaway, S., Michel, V. & Barnard, A.** (2016). Novel gene function revealed by mouse mutagenesis screens for models of age-related disease. *Nature communications*, **7**(12444).
- Rustin, P., Bourgeron, T., Parfait, B., Chretien, D., Munnich, A. & Rötig, A.** (1997). Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*, **1361**(2), pp 185-197.
- Sansbury, B. E., Jones, S. P., Riggs, D. W., Darley-USmar, V. M. & Hill, B. G.** (2011). Bioenergetic function in cardiovascular cells: the importance of the reserve capacity and its biological regulation. *Chemico-biological interactions*, **191**(1-3), pp 288-295.
- Takahashi, K. & Yamanaka, S.** (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *cell*, **126**(4), pp 663-676.
- Yadava, N. & Nicholls, D. G.** (2007). Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. *Journal of Neuroscience*, **27**(27), pp 7310-7317.

## Figures




### Figure 1 *Idh3a*<sup>E229K/E229K</sup> mice exhibit signs of retinal degeneration

**(A)** *Idh3a*<sup>E229K/E229K</sup> (red) showed a decline in visual acuity by 12 months ( $0.2071 \pm 0.01872$  c/d (mean $\pm$ SEM, n= 9, F4, M5)) compared to wild type (blue) ( $0.3090 \pm 0.009441$  c/d (mean $\pm$ SEM, n= 23, F14, M9)) ( $p < 0.0001$ ) and heterozygous (yellow) ( $0.3173 \pm 0.007472$  c/d (mean $\pm$ SEM, n= 35, F24, M11)) ( $p < 0.0001$ ). This significant decline continued and by 18 months homozygous mice had degenerated further ( $0.1592 \pm 0.02396$  c/d (mean $\pm$ SEM, n= 9 F4, M5)) compared to wild type (blue) ( $0.3004 \pm 0.01223$  c/d (mean $\pm$ SEM, n= 23 F14, M9)) ( $p < 0.0001$ ) and heterozygous (yellow)

( $0.2836 \pm 0.009699$  c/d (mean $\pm$ SEM, n= 35 F24, M11)) ( $p < 0.0001$ ). **(B)** Fundus imaging comparing *Idh3a*<sup>E229K/E229K</sup> retinas to wild type littermate; mutant retina exhibits signs of retinal degeneration as evidenced by dark patchy appearance. Unpaired Ttest \*\*\* $p < 0.001$ . **(C)** Structure of the IDH3A:IDH3G heterodimer (PDB ID: 5GRI) with the positions of the E229K mutation identified in this study (red) and previously identified missense mutations (blue) highlighted. **(D)** Predicted effects of mutations on the stability of the IDH3A monomer and on the strength of the interaction with IDH3G. Higher values indicate greater disruption of protein stability or interaction strength.






**Figure 2** *Idh3a*<sup>-/-E229K</sup> and *Idh3a*<sup>E229K/E229K</sup> mice show early and rapid photoreceptor loss

**(A)** In *Idh3a*<sup>-/-E229K</sup> mice reactive gliosis, indicated by green GFAP staining, is present from P30 and continues through P60-90, wildtype littermate control also shown (n=3). In *Idh3a*<sup>E229K/E229K</sup> retinas, this staining is not present in P30 – 60, or in wildtype littermates but is seen in P90 retinal sections (n=3). Blue staining is DAPI. **(B)** Histological analysis of Heamatoxylin and Eosin stained eyes. The numbers of nuclei in the ONL are clearly decreased in *Idh3a*<sup>-/-E229K</sup> at



P60 and almost absent by P90. **(C-D)** Numbers of photoreceptor nuclei in the outer nuclei layer (Y-axis) at fixed distances either side of the optic nerve head (X-axis). **(C)** Counts at 30 days shows that all genotypes have normal nuclei numbers, except for the periphery of *Idh3a*<sup>-/*E229K*</sup> retinas (n=3-6, data in Table S2). By P60 and continuing to P90 **(D)** the numbers of nuclei are significantly decreased in *Idh3a*<sup>*E229K/E229K*</sup> retinas (n=7 F7,M2) compared to wild type littermate controls (n=7 F4,M3). Unpaired T-test \**p* < 0.05 \*\**p* < 0.01 Scale bar 50µm. Retinal Ganglion Cell (RGC) layer, Inner Nuclei Layer (INL), Outer Nuclei Layer (ONL) and Retinal Pigmented Epithelium (RPE) layer labelled.




**Figure 3 *Idh3a*<sup>-/E229K</sup> and *Idh3a*<sup>E229K/E229K</sup> mice show normal then decreased photoreceptor function**

(A-B) A-wave amplitudes of dark adapted *Idh3a*<sup>-/E229K</sup> mice and littermate controls, exposed to a 3c.d/m<sup>3</sup> flash of light at P30 (A) and P60 (B) accompanied with traces showing mutant (red) and wild type (blue) scotopic responses at P30 (top) and P60 (bottom) (C). At P30 *Idh3a*<sup>-/E229K</sup> mice exhibit a-wave amplitudes comparable to those of control litter mates shown by one-way ANOVA (3,10) = 0.7970,  $p = 0.5232$  ( $n = 4$  (F2, M2), 3(F2, M1), 3 (F1, M2), 4 (F2, M2)) but by P60 this has significantly decreased ( $F(3,9) = 32.66$ ,  $p < 0.001$ ) ( $n = 3$ , (M3), 3 (F1, M2), 3 (F1, M2), 5, (F1, M4)).

(D-E) Comparison of a-wave amplitudes between *Idh3a*<sup>E229K/E229K</sup> and wild type controls at P60 and P120 respectively. At P60 mutant mice exhibit no loss of retinal function ( $265.5 \pm 18.18$  (mean $\pm$ SEM,  $n = 5$  F2, M3)) compared to wild type litter


mates ( $267.0 \pm 21.3$  (mean $\pm$ SEM, n= 4, F4)). By P120 photoreceptor response to a light stimulus is significantly reduced in mutant mice ( $153.2 \pm 35.11$  (mean $\pm$ SEM, n= 4 F2, M2)) compared to wild type ( $247.7 \pm 15.51$  (mean $\pm$ SEM, n= 4 F3, M1)). Accompanying traces **(F)** show *Idh3a*<sup>E229K/E229K</sup> (green) and wild type control traces (blue) at P30 (top) and P120 (bottom).



### Figure 4 Mutant MEF cells exhibit reduced reserve and maximal respiration

*Idh3a* mutants exhibit reduced mitochondrial maximum respiration and reserve capacity. **(A)** Oxygen consumption rates (OCR) of MEF cells was measured using an Agilent Seahorse XFe24 Extracellular Flux Analyser in basal and stimulated conditions. Histograms show **(B)** maximal respiration (FCCP measurement 2 – Ant/Ret measurement 2), **(C)** reserve capacity (FCCP measurement 2 – Basal measurement 2), **(D)** basal respiration (Basal measurement 2 – Ant/Ret measurement 2), **(E)** ATP respiration (Basal measurement 2 – Oligo measurement 2), **(F)** leaked respiration (Oligo measurement 2 – Ant/Ret

measurement 2)  $\text{pmol}\cdot\text{min}^{-1}\cdot\text{OD}540^{-1}$  for each part of the experiment **(A)**. *Idh3a*<sup>-</sup>/*E229K* and *Idh3a*<sup>E229K/E229K</sup> mutant cells show a lower but not significant trend in basal, ATP dependent or leaked respiration **(D-F)**. Both *Idh3a*<sup>-</sup>/*E229K* and *Idh3a*<sup>E229k/E229k</sup> showed significantly reduced maximum respiration ( $F(4,10) = 5.701, p = 0.0118$ ) **(B)** and spare respiratory capacity ( $F(4,10) = 6.536, p = 0.0075$ ) **(C)** shown by One-way ANOVA.



**Figure 5 *Idh3b*<sup>-/-</sup> mice show no signs of retinal degeneration up to six months**

*Idh3b*<sup>-/-</sup> mice show no retinal degeneration up to P180. **(A)** GFAP green immunofluorescence on retinal sections show no upregulation in mutant mice – indicating the absence of retina stress (n=3). ERG analysis of P180 *Idh3b*<sup>-/-</sup> in response to 3 c.d/m<sup>3</sup> flash under scotopic conditions shows a similar a-wave amplitude (233.4 ± 19.63 (mean±SEM, n= 6 F2, M4)) to that of wild type litter mates (207.7 ± 14.42 (mean±SEM, n= 6 F3, M3)) **(B)**. ERG traces of mutant mice (red) also show no defects when compared to wild type (black). **(C-E)** OCR was measured in *Idh3b*<sup>-/-</sup> MEF cells and compared to control litter mates. In contrast to *Idh3a* mutant cells, *Idh3b*<sup>-/-</sup> cells did not show significantly reduced maximum respiration or spare respiratory capacity. **(F)** Western blot analysis for Idh3b and Alpha tubulin in retina tissue shows the absence of Idh3b protein in *Idh3b*<sup>-/-</sup> retinas. Scale bar 50μm

	<i>Idh3a</i> <sup>-/-</sup>	<i>Idh3a</i> <sup>-/+</sup>	<i>Idh3a</i> <sup>+/+</sup>	No. Litters
Weaned	0	76	44	17
12.5	0	12	6	3
10.5	0	9	4	2
8.5	3	8	2	2

**Table 1 Genotyping of loss of function mutant**

Name	Sequence (5' – 3')
Idh3a_Guide A5	GCATTTAAACATACAGTATCA
Idh3a_Guide B3	GAAGTATGCATCAGTGCTTCC
Idh3b_Guide 1	AGGAAAGATCTATACCCCAATGG

**Table 2 CRISPR Guides**

Phenotyping Test	Parameter	Wild Type			Mutant			P value <sup>+</sup>
		Mean	SD	n	Mean	SD	n	
Bodyweight (10w)	Males(g)	32.17	4.80	46	27.92	5.07	5	0.148
	Females (g)	23.47	3.13	45	23.52	4.51	4	0.984
Echo MRI (3 Months, Males)	Fat (g)	8.7	3.23	45	5.8	2.70	5	0.076
	Lean (g)	24.5	3.01	45	22.5	4.47	5	0.382
	Fat (%)	23.2	6.21	45	18.0	5.41	5	0.101
	Lean (%)	67.5	5.42	45	72.2	6.49	5	0.194
Bodyweight (22w)	Males(g)	38.60	6.14	45	34.22	9.00	5	0.349
	Females (g)	35.69	5.90	45	35.37	7.07	4	0.936
IPGTT (5 months, Males)	Glucose t=0 (mmol/l)	10.2	2.51	45	8.88	1.41	5	0.115
	Glucose t=60 (mmol/l)	26.5	6.90	45	24.12	4.32	5	0.319
	Glucose t=120 (mmol/l)	17.3	5.40	45	13.68	3.08	5	0.058
	Insulin t=0 (µg/l)	1.0	0.40	45	0.875	0.24	5	0.348
Clinical Chemistry (6 months, Females)	Urea (nmol/l)	10.44	3.01	45	8.93	1.21	4	0.085
	Creatinine (µmol/l)	18.19	9.90	45	13.90	4.40	4	0.157
	Calcium (mmol/l)	2.40	0.13	45	2.43	0.06	4	0.439
	ALP (U/l)	89.73	19.52	45	84.40	10.82	4	0.435
	ALT (U/l)	31.18	5.11	45	29.25	2.65	4	0.262
	AST (U/l)	51.21	6.55	45	49.10	9.64	4	0.697
	Albumin (g/l)	33.60	1.93	45	34.90	1.52	4	0.208
	LDH (U/l)	371.99	86.54	45	402.95	68.41	4	0.459
Amylase (U/l)	595.73	82.96	45	607.35	132.95	4	0.875	
Bodyweight (52w)	Males(g)	46.14	7.85	40	42.72	8.68	5	0.449



	<b>Females (g)</b>	42.69	8.58	44	38.76	11.28	4	0.546
<b>Clinical Chemistry (12 months, Females)</b>	<b>Urea (nmol/l)</b>	9.07	2.34	45	10.80	2.54	4	0.280
	<b>Creatinine (µmol/l)</b>	13.79	6.70	45	21.65	13.90	4	0.345
	<b>Calcium (mmol/l)</b>	2.36	0.37	45	2.38	0.22	4	0.879
	<b>ALP (U/l)</b>	98.68	31.09	45	85.90	12.80	4	0.157
	<b>ALT (U/l)</b>	37.31	16.45	45	37.20	4.79	4	0.975
	<b>AST (U/l)</b>	61.89	21.77	45	64.95	24.42	4	0.824
	<b>Albumin (g/l)</b>	33.74	5.39	45	36.35	1.67	4	0.048*
	<b>LDH (U/l)</b>	411.96	220.92	45	877.90	773.73	4	0.316
	<b>Amylase (U/l)</b>	610.81	141.53	45	531.25	112.70	4	0.278
<b>Bodyweight (78w)</b>	<b>Males(g)</b>	47.20	7.69	22	41.31	6.36	4	0.175
	<b>Females (g)</b>	46.16	9.84	21	42.44	13.86	4	0.643
<b>Clinical Chemistry (18 months, Females)</b>	<b>Sodium (mmol/l)</b>	150.82	3.70	40	152.50	104.03	4	0.976
	<b>Potassium (mmol/l)</b>	6.32	1.81	40	7.78	3.19	4	0.434
	<b>Chloride (mmol/l)</b>	107.49	2.93	40	109.25	73.93	4	0.965
	<b>Urea (nmol/l)</b>	9.71	1.91	40	8.50	5.52	4	0.962
	<b>Creatinine (µmol/l)</b>	13.41	3.64	40	12.15	6.91	4	0.743
	<b>Calcium (mmol/l)</b>	2.42	0.23	40	2.41	1.55	4	0.991
	<b>Inorganic Phosphate (mmol/l)</b>	2.50	0.87	40	2.93	1.15	4	0.520
	<b>ALP (U/l)</b>	94.62	37.87	40	99.00	40.13	4	0.848
	<b>ALT (U/l)</b>	42.36	30.20	40	37.50	8.59	4	0.463
	<b>AST (U/l)</b>	83.87	46.77	40	70.50	26.23	4	0.415
	<b>Total Protein (g/l)</b>	53.20	3.09	40	53.18	35.43	4	0.999
	<b>Albumin (g/l)</b>	28.41	1.96	40	31.15	18.70	4	0.789
	<b>Total Cholesterol (mmol/l)</b>	4.40	0.96	40	3.73	2.43	4	0.622
	<b>HDL (mmol/l)</b>	2.86	0.58	40	2.48	1.61	4	0.671

<b>LDL (mmol/l)</b>	0.91	0.34	40	1.00	0.40	4	0.693
<b>Glucose (mmol/l)</b>	16.16	5.41	40	14.11	7.60	4	0.635
<b>Triglycerides (mmol/l)</b>	1.95	0.75	40	1.87	0.85	4	0.868
<b>Glycerol (μmol/l)</b>	574.51	222.14	40	685.00	249.17	4	0.456
<b>Free Fatty Acids (mmol/l)</b>	1.22	0.38	40	1.69	0.60	4	0.222
<b>Total Bilirubin (μmol/l)</b>	2.29	0.42	40	4.28	1.32	4	0.058
<b>LDH (U/l)</b>	498.79	164.06	40	520.50	236.69	4	0.869
<b>Amylase (U/l)</b>	608.15	86.25	40	521.75	369.04	4	0.672
<b>Creatine Kinase (U/l)</b>	169.54	160.17	40	219.00	6.63	4	0.060
<b>Uric Acid (μmol/l)</b>	278.65	134.67	40	380.67	101.81	4	0.138
<b>Fructosamine (μmol/l)</b>	228.62	44.81	40	173.25	129.97	4	0.459

**Table S1 Phenotypic analysis of *Idh3a*<sup>E229K/E229K</sup> mice**

No significant differences were observed between mutant mice and their wild type littermates apart from the 12 month Albumin concentration, however the mutant mice appear to be within normal levels and this was no longer significant by 18 months. \*Unpaired T-test with Welch's correction,


\*  $p < 0.05$

Mouse	Sex	MPC	Idh3a	Periphery 1	middle 1	nerve 1	nerve2	middle 2	periphery 2
1002	M	WT	MUT	9	9.2	9.4	11.2	10.8	9.4
1003	M	MUT	MUT	9	10.6	8.8	9.4	8.2	6.2
1004	M	WT	WT	9	12.4	11.4	10	11.2	8.4
1005	M	WT	WT	9.6	11.2	10.2	11.4	11.2	9.4
1006	M	WT	MUT	9.4	11.6	10.6	11.6	10.6	8.6
1007	F	MUT	MUT	6.2	9.2	9.4	8.6	8.8	6.4
1008	F	WT	WT	7.2	9.6	10.8	11.2	11.2	8.8
1009	F	WT	WT	9.4	11.4	9.8	10.4	11.4	9.8
1010	F	WT	MUT	8.8	11.6	10	9.2	11.4	9
1202	M	MUT	WT	11.2	12.4	10	10.2	10	10.2
1203	M	MUT	WT	8	11.6	11.4	9.4	10.4	9.6
1204	M	WT	MUT	11	12.4	10	11.4	11.6	10.2
1205	M	MUT	MUT	8	11.4	10.2	11.2	10.4	8.6
1206	F	WT	MUT	9.2	12.2	12.8	11.4	10.4	9
1207	F	WT	MUT	9.6	10.4	10.2	10.6	10.4	10.2
1208	F	WT	WT	9.2	11.2	12.2	10.6	9.2	8.2
1209	F	MUT	MUT	7	10.6	10.6	10.6	10	8.8
1210	F	WT	WT	7.8	8.2	10.4	11	11	9
1211	F	MUT	WT	10	10.4	10.6	10.6	10.8	8.4

Table S2. Outer nuclear layers of offspring of *Idh3a*<sup>E229K/-</sup> intercross. WT and MUT indicate wild-type or mutant for the particular allele. Number of nuclei in sections through the outer nuclear layer. Each is the mean of 5 counts (technical replicates).




Genotype	Average Fluorescence Intensity			
	Cell line 1	Cell line 2	Cell line 3	Cell line 4
+/+	203.128	263.989	264.796	278.359
E229K/+	322.033	294.909	327.883	
-/+	292.315	262.582	250.29	258.325
E229K/E229K	230.348	272.818	265.045	222.117
-/E229K	360	216.375	267.474	

Table S3 **Reactive Oxygen Species**: Data for Figure S3. 3 or 4 cell lines (biological replicates) from each genotype were analysed with measurements in 4 wells (technical replicates). The means of the technical replicates are shown for each biological replicate.





**Figure S1 Analysis of *Idh3a* expression and protein levels in mutant MEF cells**

**(A)** RNA was isolated from C57BL6/J mice retina and brain and RT-PCR was performed to assay the expression of *Idh3* heterotetramer components and *Idh2* genes. All were present in all samples. **(B)** Western blot showing the reduced protein in *Idh3a*<sup>-/+</sup> and *Idh3a*<sup>-/E229K</sup> compared to control littermates (*Idh3a*<sup>+/+</sup> and *Idh3a*<sup>E229K/E229K</sup>) as well as *Idh3a*<sup>E229K/E229K</sup> mutant cells. Alpha-tubulin was used as a loading control.



**Figure S2 Analysis of *Idh3a*<sup>-/-</sup> mice show no retinal phenotype up to one year**

**(A)** *Idh3a*<sup>-/-</sup> mice show no upregulation of GFAP at one year, with staining comparable to that of wild type littermates (n = 3). **(B)** Morphology of retinal layers, including the outer nuclear layer, appears normal at 12 months and is comparable to that of wild type littermates (n = 6). **(C)** *Idh3a*<sup>-/-</sup> mutant mice show no reduction in retinal function at one year, exhibiting similar ERG a-wave responses to those of wild type littermates ( $p = 0.286$ , n = 4).





**Figure S3 Further analysis of MEF cell lines**

**(A)** Reactive Oxygen Species (ROS) were measured in each of the cell lines, both *Idh3a*<sup>-/E229K</sup> and *Idh3a*<sup>E229K/E229K</sup> cells showed levels similar to that of control cells (*Idh3a*<sup>+/+</sup>, *Idh3a*<sup>-/+</sup> and *Idh3a*<sup>E229K/+</sup>), graph shows fluorescent intensity in arbitrary units Data is in Table S3. **(B)** Western blot analysis of MEF cell lines showing similar levels of mitochondrial proteins; Complex II, Complex IV and Complex V. Alpha-tubulin was used as a loading control.